Search results - found 82
The economics of judicial patent reform in the United States (Market intelligence)
The patent landscape in the United States is in the midst of significant change. This stems largely from systemic reform efforts aimed at addressing a patent system many consider to be out of sync with today’s business realities
Just say no to a broad research use exemption in the US (Market intelligence)
Innovation depends on patents. Patents advance both industrial application and scientific research by getting technologies to be used broadly and rapidly. As a result, arguments to weaken or eliminate the enforceability of patents in research areas such as biotechnology or nanotechnology are seriously misguided.
The patent opposition system in India (Market intelligence)
The Indian patent system was revolutionised on 1st January 2005, when the doors were finally opened to product patents for food, chemicals and pharmaceuticals. However, while the new patent regime offers a wealth of new opportunities to innovator companies, it has also been dogged by increasing backlogs, delays in grant and the constant risk that patents are open to challenge at any stage.
The hoo-ha about Hoodia in South Africa (Market intelligence)
The Hoodia plant is a relatively unspectacular succulent of the genus Hoodia, of which a number of species are indigenous to Southern Africa. Were it not for the fact that the plant contains certain chemicals that appear to act as appetite suppressants, the Hoodia cactus would be of little interest to anyone other than botanists.
Issues for pharmaceutical companies doing business in Australia (Market intelligence)
The Australian pharmaceutical market is both highly competitive and highly regulated. There are a myriad of legal issues with which any pharmaceutical company conducting business in Australia must contend. Some of the current patent-related issues of relevance to pharmaceuticals in Australia are reviewed below.
The European Patent Convention and the London Agreement (Market intelligence)
The European Patent Convention (EPC 2000) came into force on 13th December 2007, introducing sweeping changes to the European patent system. The new convention governs the granting of European patents by the European Patent Office (EPO) and applies throughout the 34 contracting states of the European Patent Organisation (ie, the 27 EU Member States as well as Croatia, Iceland, Liechtenstein, Monaco, Norway, Switzerland and Turkey).
Buyer beware: an IP checklist for life sciences investors (Market intelligence)
Whether caused by the paucity of new products in pharma pipelines or the lure of a highly marketable new technology, investors often become comfortable with a deal before effectively evaluating the target’s intellectual property portfolio. IP issues that are overlooked often decrease the value of the investment and open the door for future debilitating litigation.
Novelty of biotechnological inventions and further therapeutic use in Europe (Market intelligence)
This article analyses recent European case law and changes following the entry into force of the European Patent Convention (EPC) 2000 in relation to the assessment of the novelty of certain biotechnological inventions, including claims to products and method/use claims.
New Mexican marketing authorisation and data exclusivity regulations (Market intelligence)
On 2nd January 2008 a decree was published in Mexico’s Official Gazette modifying several provisions of the Health Law Regulations for Health Consumables. The changes have important implications for the pharmaceutical industry.
Building a strong patent portfolio (Market intelligence)
Patents are tangible assets which, if properly managed and utilised, create increased value in a company. One of the commercial impacts of a strong patent portfolio is a strategic collaboration or alliance between a pharmaceutical giant and biotechnology company. Patents provide a tangible value in that they are often a means for attracting investors or providing a source of revenue through patent licensing.
Litigating biotech patents in Europe (Market intelligence)
Litigation around Europe relating to biotechnology patents is likely to increase significantly over the coming years as biologics form an increasing number of newly approved medicines. Two high-profile biotech cases have just been heard by the UK patents court: Monsanto v Cargill 2007 EWHC 2257 and Eli Lilly v HGS (judgment awaited).
Generics and biogenerics in Brazil (Market intelligence)
As technology evolves to meet the challenges facing humanity, one constant is the fight against diseases affecting large parts of society. The development of new technologies for health products and medicines is thus a key priority.
Welcome (Market intelligence)
It is a pleasure to welcome you to IP in the Life Sciences Industries 2009, a special supplement of Intellectual Asset Management magazine.
Managing IP in open innovation partnerships (Market intelligence)
Open innovation is growing in popularity as an increasing number of companies seek to collaborate on research and product development. However, for the process to work, it is vital that all the IP angles are understood and acted upon
Taking the heat out of the global patent system (Market intelligence)
Global patent warming is real, not imaginary. And while it may suit some, for many others it will cause increasing problems. At the world’s major patent offices, solutions are being sought. It could all mean that change is on the way
Exclusive marketing rights revisited in India (Market intelligence)
Interest in the repealed exclusive marketing rights provisions has been revived by a Supreme Court ruling which clarifies the effect of the repeal on the litigation of pending and decided applications
Life sciences patent strategies in Europe (Market intelligence)
The European market can be a daunting one, due to the lack of a unified patent system. However, life sciences companies can employ a number of tactics in order to arrive at a successful IP strategy for patent protection
IP issues in outsourcing R&D (Market intelligence)
Life sciences companies are increasingly outsourcing R&D to keep pace with scientific and technological advancements and tougher regulatory demands. In selecting the optimal approach, they must take care to assess the opportunities and potential pitfalls
Key IP issues for life sciences companies doing business in China (Market intelligence)
Life sciences companies seeking to crack the challenging yet lucrative Chinese market must arm themselves with the necessary knowledge to minimise risk and maximise gain
Protecting biotech inventions in Europe (Market intelligence)
The question of what constitutes patentable subject matter is particularly relevant to biotech inventions, not least due to the ethical issues they present. Answers can be found in the EPC 2000 and in EPO case law and practice
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email